there were no statistically significant differences between the two groups in underlying pathology and in the clinical results obtained : septicaemia 20/26 patients of the imipenem group and 20/25 patients of the cefotaxime-amikacin group were cured ;
C0036690
septicaemia
C0002499
amikacin